Therapy Areas: Infectious Diseases
Chess Named to BigHat Biosciences Board of Directors
12 May 2022 - - Rob Chess has been elected to US-based biotechnology company BigHat Biosciences' board of directors, the company said.

Rob brings valuable experience in corporate biotech leadership and business strategy, from having led innovative and diverse teams from inception to successful exits to serving on the boards of multiple private and public life sciences companies.

Rob Chess is the former CEO and current chairman of Nektar Therapeutics, (NASDAQ: NKTR), a health care biotechnology company; serves as lead director of Twist Biosciences (NASDAQ: TWST), a company in the field of synthetic biology; and lectures at Stanford's Graduate School of Business.

Previously, Rob co-founded Biota Technologies, a pioneer of DNA sequencing for energy and industrial applications, Penederm, a dermatology company acquired by Mylan Laboratories; was the first CEO of OPX Biotechnologies, a renewable chemicals company sold to Cargill.

Founded in 2019, BigHat Biosciences is an early-stage biotechnology company in the San Francisco Bay Area. BigHat is led by a team of experts spanning machine learning, molecular biology, drug development, and medicine.

BigHat is supported by a cadre of leaders, including a Nobel Laureate and the physician-scientist that brought Herceptin to market.

To date, BigHat has raised USD 25m from top investors led by a16z and 8VC and is quickly succeeding in partnerships with large biopharma partners.

In addition to these collaborations, BigHat has active therapeutic programs spanning multiple domains of human health, including inflammation, oncology, hematology, and infectious diseases in preclinical studies.
Login
Username:

Password: